Importantly, the aberrant expression of IL-6 in GBM cells is also interrupted by Ad-bFGF-siRNA (Figure 3), which could be a potential mechanism for Ad-bFGF-siRNA to serve as a targeted therapy for glioma in vitro and in vivo. Here, FGF2 is linked to glioblastoma.